Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
Open Access
- 1 May 2010
- journal article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. 4, 127-133
- https://doi.org/10.2147/PPA.S10468
Abstract
Peer reviewed article authored by (William Camu, Karim Hadjout, Sabine Latour, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 12 references indexed in Scilit:
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialThe Lancet Neurology, 2008
- Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology, 2006
- Patient satisfaction with an injection device for multiple sclerosis treatmentActa Neurologica Scandinavica, 2006
- Corticosteroids, ibuprofen, and acetaminophen for IFNβ-1a flu symptoms in MSNeurology, 2004
- Randomized, comparative study of interferon β-1a treatment regimens in MSNeurology, 2002
- Managing the Adverse Effects of Interferon-?? Therapy in Multiple SclerosisDrug Safety, 2000
- Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Effect Sizes for Interpreting Changes in Health StatusMedical Care, 1989